Alnylam Pharma (ALNY) Misses Q2 EPS by 10c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $245.51 +2.57%
EPS Growth %: -39.0%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
ALZN, ASPU, USAU, More
EPS Growth %: -39.0%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of ($1.62), $0.10 worse than the analyst estimate of ($1.52). Revenue for the quarter came in at $305.7 million versus the consensus estimate of $332.83 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald’s said to plan value strategy overhaul to revive US sales growth
- Investec Double Upgrades Supreme Industries (SI:IN) to Buy
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
